SEATTLE--(BUSINESS WIRE)--Nativis, Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that Charles (Charlie) McNerney has been appointed to the Company’s Board of Directors.
McNerney has over 24 years of multi-disciplinary experience in the technology sector. This ranges from physical and digital security protection to privacy and compliance. McNerney was previously the Chief Information Security Officer for Microsoft and CISO of the company’s digital properties such as MSN. McNerney has designed and implemented several innovative security solutions that maintain a high degree of security while not impacting the overall agility needed by a Fortune 50 technology company. McNerney comes with deep technical depth: he has often been a keynote presenter, and has hosted international companies, at Microsoft’s key security briefings; and he co-authored “Securing the Microsoft Cloud.” McNerney is currently Vice President, Engineering and Operations at Microsoft for Retail.
Chris Rivera, Nativis’ Chief Executive Officer, commented, “We are pleased to have Mr. McNerney join our Board of Directors. We believe his deep technical knowledge of physical and digital security design will be of significant importance as we continue to develop our proprietary ulRFE™ technology. We look forward to his contributions to Nativis as we work together to fully realize the potential of our technology and the Nativis Voyager® system.”
McNerney added, “Nativis’ innovative ulRFE technology and non-invasive approach to disease treatment presents a compelling opportunity in Glioblastoma Multiforme and potentially wider treatment applications. I look forward to leveraging my expertise in building secure environments, systems development and testing, and manufacturing and supply chain management as Nativis moves forward with the clinical development and engineering of the Nativis Voyager® system as well as the development of new digital cognates from solvated molecules.”
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.